Zhao Guang Sheng, Liu Ying, Zhang Qing, Li Chuang, Zhang Yue Wei, Ren Zhi Zhong, Zhou Jun, Zhang Ming
Department of Interventional Therapy, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Department of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Central Laboratory, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Department of Hepatobiliary Intervention, Beijing Tsinghua Changgung Hospital, Changping, Beijing, China.
Medicine (Baltimore). 2017 Jul;96(29):e7589. doi: 10.1097/MD.0000000000007589.
To evaluate the safety and efficacy of transarterial arterial chemoembolization (TACE) with gelatin sponge particles (GSPs-TACE) and Huaier granule to treat primary hepatic carcinoma (PHC).A series of 62 patients with PHC were included between June 2009 and December 2011, and randomly assigned to a control (n = 31) or an experimental group (n = 31). The control patients received TACE with 350 to 560 μm GSPs plus lobaplatin chemotherapy. Patients in the experimental group received TACE plus Huaier granule. Treatment safety and mid-to-long-term efficacy were evaluated.Follow-up ranged from 12 to 24 months with a mean of 28.7 months. The 6- and 12-month overall survivals were 100% and 93.5% in the experimental group and 90.3% and 80.6% in control group, respectively. The difference in overall survival at 12 months was significant (χ = 5.213, P < .05), but the difference in median survival in the experimental group (20.6 months) and control group (17.1 months) patients was not significant (χ = 0.745, P > .05). The number of TACE procedures in the experimental group (2.9 ± 8.7) and control group (4.1 ± 7.3) patients was significantly different (χ = 7.262, P < .05). The 6-month (87.1% vs. 73.3%, χ = 5.945) and 12-month (72.4% vs. 64.3%, χ = 6.384) tumor objective response rates in the experimental and control groups were significantly different (P < .05). There were no statistically significant differences in the occurrence of treatment-related adverse reactions in the 2 groups.Transarterial chemoembolization with GSPs and Huaier granule was safe and effective for treating PHC patients.
评估经动脉动脉化疗栓塞术（TACE）联合明胶海绵颗粒（GSPs-TACE）及槐耳颗粒治疗原发性肝癌（PHC）的安全性和疗效。2009年6月至2011年12月纳入62例PHC患者，随机分为对照组（n = 31）和实验组（n = 31）。对照组患者接受350至560μm GSPs的TACE联合洛铂化疗。实验组患者接受TACE联合槐耳颗粒。评估治疗安全性和中长期疗效。随访时间为12至24个月，平均28.7个月。实验组6个月和12个月的总生存率分别为100%和93.5%，对照组分别为90.3%和80.6%。12个月时总生存率差异有统计学意义（χ = 5.213，P <.05），但实验组（20.6个月）和对照组（17.1个月）患者的中位生存时间差异无统计学意义（χ = 0.745，P >.05）。实验组（2.9 ± 8.7）和对照组（4.1 ± 7.3）患者的TACE次数差异有统计学意义（χ = 7.262，P <.05）。实验组和对照组6个月（87.1%对73.3%，χ = 5.945）和12个月（72.4%对64.3%，χ = 6.384）的肿瘤客观缓解率差异有统计学意义（P <.05）。两组治疗相关不良反应的发生率无统计学差异。GSPs联合槐耳颗粒的经动脉化疗栓塞术治疗PHC患者安全有效。
